Atopic Dermatitis

ARCADIA LTE data show nemolizumab maintains EASI-75 in over 90% of responders through 2 years and phase 2 pediatric data shed further light at RAD 2026.

A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.

RAD 2026 analyses reveal the impact of CHE on patients' lives, including its financial effects and influence on treatment decision-making.

Real-world data from the international TRACE study show 12 months of tralokinumab improved skin and quality-of-life outcomes.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

In the final segment, the clinicians evaluate the guideline's nuanced positioning of phototherapy relative to newer systemic agents and highlight a gap.

Krakowski and Torres-Zegarra discuss how to initiate the conversation about systemic therapy with families and review the guideline's drug hierarchy.

The experts review the guideline's approach to topicals for active atopic dermatitis, covering the appropriate use of topical corticosteroids and more.

This segment examines how the guideline navigates the tension between GRADE-based evidence thresholds and long-established clinical practices.

This discussion highlights disease prevention and the foundational role of moisturization, with the experts examining emollient use.

Pediatric dermatologists introduce the first pediatric-specific evidence-based guidelines for atopic dermatitis and discuss.

This Q&A interview highlights findings on the lifelong impacts on education and career faced by some patients with childhood diagnoses of atopic dermatitis.

Delphine Kerob, MD, in this segment of her interview, expanded on the clinical implications of new data on atopic dermatitis and lifelong impacts.

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.

This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.

A new phase 3 study is evaluating lebrikizumab in at least 270 patients with nummular eczema over 48 weeks.

Patients with atopic dermatitis and prurigo nodules (AD-PN) saw notable itch reduction in 12 weeks after initiating upadacitinib.

New OX40 biologics aim for longer atopic dermatitis control, but Kaposi's sarcoma concerns split experts as amlitelimab advances and rocatinlimab halts.

In this segment of his interview, Chovatiya speaks about how new consensus definitions on atopic dermatitis disease activity could impact clinical trials.